Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Bon Secours Memorial Regional Medical Center
mi
from
Mechanicsville, VA
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Bon Secours Memorial Regional Medical Center
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Shenandoah Oncology Associates, PC
mi
from
Winchester, VA
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Shenandoah Oncology Associates, PC
mi
from
Winchester, VA
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Providence Regional Cancer Partnership
mi
from
Everett, WA
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
West Virginia University Charleston
mi
from
Charleston, WV
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
West Virginia University Charleston
mi
from
Charleston, WV
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Langlade Hospital and Cancer Center
mi
from
Antigo, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Langlade Hospital and Cancer Center
mi
from
Antigo, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Aurora Cancer Care-Southern Lakes VLCC
mi
from
Burlington, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Aurora Cancer Care-Southern Lakes VLCC
mi
from
Burlington, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Mayo Clinic Health System-Eau Claire Clinic
mi
from
Eau Claire, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Mayo Clinic Health System-Eau Claire Clinic
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Aurora Health Care Germantown Health Center
mi
from
Germantown, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Aurora Health Care Germantown Health Center
mi
from
Germantown, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Mercy Health System
mi
from
Janesville, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Mercy Health System
mi
from
Janesville, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
William S Middleton VA Medical Center
mi
from
Madison, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
William S Middleton VA Medical Center
mi
from
Madison, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
HSHS Saint Nicholas Hospital
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Aspirus UW Cancer Center
mi
from
Wisconsin Rapids, WI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Aspirus UW Cancer Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Hawaii Oncology Inc-Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Pali Momi Medical Center
mi
from
'Aiea, HI
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Pali Momi Medical Center
mi
from
'Aiea, HI
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Memorial Sloan-Kettering Cancer Center West Harrison
mi
from
Harrison, NY
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Memorial Sloan-Kettering Cancer Center West Harrison
mi
from
Harrison, NY
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Novant Health Oncology Specialists-Statesville
mi
from
Statesville, NC
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Novant Health Oncology Specialists-Statesville
mi
from
Statesville, NC
Click here to add this to my saved trials
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Wright-Patterson Medical Center
mi
from
Wright-Patterson Air Force Base, OH
Click here to add this to my saved trials
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients
Status: Enrolling
Updated:  4/6/2018
UCSF Imaging Center at China Basin
mi
from
San Francisco, CA
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients
Status: Enrolling
Updated: 4/6/2018
UCSF Imaging Center at China Basin
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
START Midwest
mi
from
Grand Rapids, MI
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
START Midwest
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
Massachusetts General Hospital
mi
from
Boston, MA
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
Moffitt Cancer Center
mi
from
Tampa, FL
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated:  4/6/2018
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated: 4/6/2018
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
USC University of Southern California Keck School of Medicine
mi
from
Los Angeles, CA
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
USC University of Southern California Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
UM Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
UM Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Northwestern University
mi
from
Chicago, IL
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Rush University Medical Center
mi
from
Chicago, IL
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
University of Chicago
mi
from
Chicago, IL
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Weiss Memorial Hospital
mi
from
Chicago, IL
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Weiss Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
AP&S Clinic
mi
from
Terre Haute, IN
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
AP&S Clinic
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
University of Kansas Cancer Center
mi
from
Kansas City, KA
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
University of Kansas Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Henry Ford Health System
mi
from
Detroit, MI
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Kansas City VA Medical Center
mi
from
Kansas City, MO
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Kansas City VA Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  4/6/2018
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 4/6/2018
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials